These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 3809196)

  • 1. Preclinical antitumor activity of batracylin (NSC 320846).
    Plowman J; Paull KD; Atassi G; Harrison SD; Dykes DJ; Kabbe HJ; Narayanan VL; Yoder OC
    Invest New Drugs; 1988 Sep; 6(3):147-53. PubMed ID: 3192381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic cancer chemotherapy: obstacles and future pharmacologic aspects and selective toxicity.
    Goldin A
    Cancer Clin Trials; 1978; 1(2):119-27. PubMed ID: 757140
    [No Abstract]   [Full Text] [Related]  

  • 5. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possible modality for overcoming drug resistance].
    Tsuruo T
    Rinsho Ketsueki; 1985 Jun; 26(6):877-9. PubMed ID: 4068249
    [No Abstract]   [Full Text] [Related]  

  • 7. Pleiotropic resistance and drug development.
    Shoemaker R; Wolpert-DeFilippes M; Plowman J; Abbott B; Venditti J; Trader M; Griswold D; Gerlach J; Ling V
    Prog Clin Biol Res; 1986; 223():143-9. PubMed ID: 3809196
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.
    Ramu A; Shan TC; Glaubiger D
    Cancer Treat Rep; 1983 Oct; 67(10):895-9. PubMed ID: 6354437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of cross-resistance profiles for new agents.
    Schabel FM; Skipper HE; Trader MW; Laster WR; Griswold DP; Corbett TH
    Cancer Treat Rep; 1983 Oct; 67(10):905-22. PubMed ID: 6354439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anthracycline analogs.
    Grandi M; Pezzoni G; Ballinari D; Capolongo L; Suarato A; Bargiotti A; Faiardi D; Spreafico F
    Cancer Treat Rev; 1990 Sep; 17(2-3):133-8. PubMed ID: 2272029
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of responses to therapy and mechanisms of resistance.
    Hall TC
    Semin Oncol; 1977 Jun; 4(2):193-202. PubMed ID: 327553
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug resistance.
    Rodenhuis S
    Curr Opin Oncol; 1989 Dec; 1(2):236-40. PubMed ID: 2489966
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.